DGAP-News: Pulmo BioTech Inc: Pulmo BioTech Inc Announces Completion of Regulatory Approval Work

Pulmo BioTech Inc / Research Update

02.03.2009 

Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Frankfurt, Germany, March 2, 2009/EquityStory AG -- Pulmo BioTech Inc. (OTC
Bulletin Board: PLMO.OB; Frankfurt Borse (symbol PBO)) has announced that
its subsidiary, PulmoScience Inc., has successfully completed all of the
experimental work required for Regulatory Approval to commence Phase I
Human Trials.

'With the completion of the Purity Studies, the company has now met all of
the requirements that had been agreed with the Regulatory Authority as
precursors to Phase I Trials. We are very pleased with the results, and we
will be formally submitting our report to the Regulatory Authority for
permission to commence Phase I Human Trials of our PulmoBind pulmonary
imaging agent' - Garry McCann, CEO Pulmo BioTech Inc.


About Pulmo BioTech Inc. 

Pulmo BioTech Inc. specializes in the development and marketing of medical
technology and research. Our proven strengths combine extensive commercial
experience and academic credentials. The principal staff members are
acknowledged experts in their specialized fields, and work with a broad
range of investment institutions. Our mission is to utilize scientific
imagination and drive, together with managerial and financial acumen, to
bring innovative and profitable products to the marketplace to the benefit
of all stock holders.

ISIN: US7458451074

CUSIP: 745845107


About PulmoScience Inc. 

PulmoScience Inc. was established in 2006, and is currently developing a
non-invasive Molecular Imaging technique for the diagnosis of Pulmonary
Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the
trade name PulmoBind.

PulmoScience was conceived within the Montreal Heart Institute 'MHI' (a
world renowned hospital and educational facility). Jointly owned by MHI
subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn
Dupuis (the scientific director and originator of the PulmoBind Molecular
Imaging technology), and by Pulmo BioTech Inc. as the funding partner,
PulmoScience Inc. aims to develop this unique and exciting technology, to
fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth
in excess of $500 million per annum and that, provided Regulatory Approval
is achieved, the safety and efficacy of its products could allow it to
dominate that market.


About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged molecule
which specifically bonds to the inner walls of the circulatory system in
the lungs, and by the use of an external Gamma Camera allows an image of
the integrity of the blood vessels throughout the lungs to be seen by a
diagnostic clinician. PulmoScience is currently undertaking Regulatory
Approval for Phase I Human Trials, and while subsequent results from
additional tests might not corroborate the current results, PulmoScience
believes that PulmoBind has the potential to dominate the market for the
diagnosis of Pulmonary Embolism.  In particular, this belief is driven by
PulmoScience's expectations of the improved safety and efficacy that
PulmoBind will offer when compared to the current incumbent nuclear
medicine based technology for the diagnosis of Pulmonary Embolism.  In
addition, early indications are that PulmoBind could be highly effective in
the early stage diagnosis of Pulmonary Hypertension, a condition for which
there is no current front line diagnostic test. The addressable market for
the product candidates being developed by PulmoScience is believed by the
company to be worth in excess of $500 million per annum.


Further Information

For further information regarding Pulmo BioTech Inc or PulmoScience, please
visit www.pulmobiotech.com



Forward-Looking Statements

Forward-looking statements contained in this and other written and oral
reports are made based on known events and circumstances at the time of
release, and as such, are subject in the future to unforeseen uncertainties
and risks. All statements regarding future performance, earnings
projections, regulatory approval, events or developments are
forward-looking statements. It is possible that the future performance of
the company may differ materially from current expectations, depending on
economic conditions and the uncertainty of regulatory approval. A change in
economic conditions may have a particularly volatile effect on results.
Among the other factors which may affect future performance are:
competitive market conditions and resulting effects on sales and pricing;
increases in raw-material costs that cannot be recovered in product
pricing; and global economic factors, including difficulties entering new
markets and general economic conditions such as inflation, interest rates
and credit availability. The company makes these statements as of the date
of this disclosure, and undertakes no obligation to update them.
DGAP 02.03.2009 
---------------------------------------------------------------------------